Accumulation of major linezolid metabolites in patients with renal impairment

Ernane Souza, Ryan L. Crass, Jeremy Felton, Kengo Hanaya, Manjunath P. Pai

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


In patients with renal impairment (n=22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations (r2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.

Original languageEnglish
Article numbere00027-20
JournalAntimicrobial Agents and Chemotherapy
Issue number5
Publication statusPublished - 2020 May 1


  • Dialysis
  • Myelosuppression
  • Oxazolidinones
  • Pharmacodynamics
  • Toxicology

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Accumulation of major linezolid metabolites in patients with renal impairment'. Together they form a unique fingerprint.

Cite this